Inflammatory risk and clinical outcomes according to polyvascular atherosclerotic disease status in patients undergoing PCI
Authors:
- 20 June 2024
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 114 (8) , 969-977
Abstract
Background Individuals suffering from polyvascular atherosclerotic disease (PolyVD) face a higher likelihood of adverse cardiovascular events. Additionally, inflammation, assessed by high-sensitivity C-reactive protein (hsCRP), affects residual risk following percutaneous coronary intervention (PCI). We aimed to explore the interplay between PolyVD and hsCRP in terms of clinical outcomes after PCI. Methods Patients undergoing PCI for chronic coronary disease at a tertiary center between January 2012 and February 2020 were included for the current analysis. PolyVD was defined by additional history of cerebrovascular and/or peripheral artery disease. HsCRP levels were defined as elevated when the measured baseline concentration was > 3 mg/L. The primary outcome of interest was major adverse cardiovascular events (MACE), a composite of all-cause mortality, spontaneous MI, or target vessel revascularization. Results Overall, 10,359 participants were included in the current study, with 17.4% affected by PolyVD and 82.6% included in the non-PolyVD subgroup. Patients with PolyVD had higher hsCRP levels than those without. Among the PolyVD group, a larger proportion (33.6%) exhibited elevated hsCRP compared to the non-PolyVD group (24.7%). Patients with both PolyVD and elevated hsCRP levels had significantly higher adverse event rates than all other subgroups at 1-year follow-up. Furthermore, an independent association between elevated hsCRP and MACE was observed within the PolyVD population, while this was not the case for individuals without PolyVD. Conclusion A residual risk of adverse outcomes after PCI linked to inflammation appears to be present among individuals with PolyVD. This could help define further target populations for anti-inflammatory treatment options. Graphical AbstractKeywords
Funding Information
- Deutsche Herzstiftung (S/06/23)
This publication has 29 references indexed in Scilit:
- The prevalence of polyvascular disease in patients with carotid artery disease and peripheral artery diseasePolish Heart Journal, 2019
- Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeNew England Journal of Medicine, 2018
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseNew England Journal of Medicine, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary interventionEuroIntervention, 2016
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine, 2015
- Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non–ST-Segment–Elevation Myocardial InfarctionCirculation: Cardiovascular Quality and Outcomes, 2012
- The Prevalence of Polyvascular Disease in Patients Referred for Peripheral Arterial DiseaseEuropean Journal of Vascular and Endovascular Surgery, 2009
- Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromesEuropean Heart Journal, 2009
- Markers of Inflammation and Cardiovascular DiseaseCirculation, 2003